Ironwood Pharmaceuticals

Last updated
Ironwood Pharmaceuticals, Inc.
Company type Public
Nasdaq:  IRWD (Class A)
Russell 2000 Component
S&P 600 component
Founded1998;26 years ago (1998)
HeadquartersBoston, Massachusetts
Website ironwoodpharma.com

Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.

Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. [1] [2] In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, [3] which at the time were focused on identifying small molecules that could inhibit fungal invasins, [3] [4] along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, [1] and also Richard Bailey, who had run Monsanto's nutritional business. [2] Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea. [5] [6]

By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide. [1] By 2006 Microbia was starting to struggle with the different challenges and expenses of drug development, along with its industrial fermentation business and drug discovery efforts, and made the decision to split in two, with "Microbia Precision Engineering" focused on industrial applications led by Bailey and Microbia focused on drug discovery and development. [2] Tate & Lyle invested $7M in the Microbia spinout and took a board seat in 2006. [2] Microbia changed its name to Ironwood in 2008 and shortened the name of the industrial business to Microbia. [7]

By 2009, Ironwood had raised a total of $281M. [2] In early 2010 Ironwood held its IPO, which priced at $11.25 a share, below the target price of $14. [8] Later that year it sold its interests in Microbia to DSM for an undisclosed sum. [9]

Linaclotide (Linzess in the US and Mexico, and as Constella elsewhere), [10] a drug used to treat irritable bowel syndrome with constipation and chronic constipation with no known cause, was approved in the US and Europe in 2012. [11] [12] Most of the marketing rights were licensed to Allergan and Astellas. [13] [14] [15]

It was developing a drug called IW-9179 or recanaclotide but abandoned it in 2016. [16]

BNC210 is an anxiolytic that Ironwood licensed and performed R&D on and then abandoned. [17]

In April 2018, the shares of Ironwood Pharmaceuticals closed up more than 10 percent on the news of biotech activist investor, Alex Denner joining its board. [18]

Related Research Articles

<span class="mw-page-title-main">Pharmacia & Upjohn</span> Global pharmaceutical company

Pharmacia & Upjohn was a global pharmaceutical company formed by the merger of Sweden-based Pharmacia AB and the American company Upjohn in 1995. Today the remainder of the company is owned by Pfizer. In 1997, Pharmacia & Upjohn sold several brands to Johnson & Johnson, including Motrin and Cortaid.

<span class="mw-page-title-main">Alosetron</span> Medication

Alosetron, sold under the brand name Lotronex among others, is a 5-HT3 antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in females only.

<span class="mw-page-title-main">Tegaserod</span> Medication

Tegaserod is a 5-HT4 agonist manufactured by Novartis and sold under the names Zelnorm and Zelmac for the management of irritable bowel syndrome and constipation. Approved by the FDA in 2002, it was subsequently removed from the market in 2007 due to FDA concerns about possible adverse cardiovascular effects. Before then, it was the only drug approved by the United States Food and Drug Administration to help relieve the abdominal discomfort, bloating, and constipation associated with irritable bowel syndrome. Its use was also approved to treat chronic idiopathic constipation.

<span class="mw-page-title-main">Renzapride</span> Chemical compound

Renzapride is a prokinetic agent and antiemetic which acts as a full 5-HT4 agonist and partial 5-HT3 antagonist. It also functions as a 5-HT2B antagonist and has some affinity for the 5-HT2A and 5-HT2C receptors.

Forest Laboratories was a company in the pharmaceutical industry incorporated in Delaware, with its principal office in New York City. It was known for licensing European pharmaceuticals for sale in the United States. On July 1, 2014, the company was acquired by Actavis.

<span class="mw-page-title-main">Olsalazine</span> Pharmaceutical drug

Olsalazine is an anti-inflammatory medication used in the treatment of ulcerative colitis. It is sold under the brand name Dipentum.

<span class="mw-page-title-main">Trospium chloride</span> Chemical compound

Trospium chloride is a muscarinic antagonist used to treat overactive bladder. It has side effects typical of this class of drugs, namely dry mouth, stomach upset, and constipation; these side effects cause problems with people taking their medicine as directed. However it doesn't cause central nervous system side effects like some other muscarinic antagonists. It is in pregnancy category C and is excreted in breast milk.

<span class="mw-page-title-main">Lubiprostone</span> Medication used for constipation

Lubiprostone, sold under the brand name Amitiza among others, is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. The drug is owned by Mallinckrodt and is marketed by Takeda Pharmaceutical Company.

<span class="mw-page-title-main">Amylin Pharmaceuticals</span> Biopharmaceutical company

Amylin Pharmaceuticals, Inc. is a biopharmaceutical founded in 1987 that was based in San Diego, California. The company was engaged in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. Amylin produced three drugs: Symlin, Byetta (exenatide) and Bydureon.

<span class="mw-page-title-main">Basilea Pharmaceutica</span> Swiss pharmaceutical company

Basilea Pharmaceutica is a multinational specialty biopharmaceutical company headquartered in Basel, Switzerland. It was formed as a spin-off entity from the drug giant Hoffmann–La Roche in October 2000. It is engaged in the development of antibiotics, antifungals and oncology drugs for treatment of invasive aspergillosis and mucormycosis. Basilea is publicly traded on the SIX Swiss exchange.

Rose Pharma is a private company that was founded in 2003 as Gastrotech Pharma and is located in Copenhagen, Denmark. The company is led by CEO Leif Helth Jensen, who is, together with Michael Forer and Florian Schönharting, also member of the Board of Directors. Rose Pharma is a clinical stage biotechnology company focused on the development of novel treatments for IBS and anorexia/cachexia associated with cancer and other major pathologies.

SUGEN (Sugen) was a drug discovery company focused on development of protein kinase inhibitors. It was founded in 1991, and shut down in 2003, after pioneering protein kinases as therapeutic targets and developing the successful cancer therapy sunitinib (Sutent).

<span class="mw-page-title-main">Nathaniel David</span> American scientist and entrepreneur

Nathaniel David is an American scientist and entrepreneur who co-founded a series of technology companies in the biotechnology and sustainable energy sectors, including Syrrx, Achaogen, Kythera Biopharmaceuticals, Sapphire Energy and Unity Biotechnology. These companies have collectively raised more than $1.5 billion in financing.

Christoph Westphal is an American biomedical businessman.

<span class="mw-page-title-main">Linaclotide</span> Medicine

Linaclotide, is a drug used to treat irritable bowel syndrome with constipation and chronic constipation with no known cause. It has a black box warning about the risk of serious dehydration in children in the US; the most common adverse effects in others include diarrhea.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

<span class="mw-page-title-main">Deuterated drug</span>

A deuterated drug is a small molecule medicinal product in which one or more of the hydrogen atoms in the drug molecule have been replaced by its heavier stable isotope deuterium. Because of the kinetic isotope effect, deuterium-containing drugs may have significantly lower rates of metabolism, and hence a longer half-life.

<span class="mw-page-title-main">Eluxadoline</span> Chemical compound

Eluxadoline, sold under the brand names Viberzi and Truberzi, is a medication taken by mouth for the treatment of diarrhea and abdominal pain in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D). It was approved for use in the United States in 2015. The drug originated from Janssen Pharmaceutica and was developed by Actavis.

Plecanatide, sold under the brand name Trulance, is a medication for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation. It is being launched in India under the brand name "Plecasoft". Plecanatide is an agonist of guanylate cyclase-C. Plecanatide increases intestinal transit and fluid through a buildup of cGMP.

References

  1. 1 2 3 Withers, Melissa (September 22, 2004). "Drug hunters". Whitehead Institute .
  2. 1 2 3 4 5 Timmerman, Luke (23 February 2009). "Xconomy: Renewables Aren't Just for Biofuels: Microbia Makes Industrial Chemicals a Bit Greener". Xconomy. Archived from the original on 16 April 2018.
  3. 1 2 Langreth, Robert (June 23, 2003). "The Chemical Cobbler". Forbes.
  4. ↑ McCarthy, Alice A. (February 2003). "Microbia" (PDF). Chemistry & Biology. 10 (2): 99–100. doi: 10.1016/S1074-5521(03)00031-0 . PMID   12618178.
  5. ↑ Hornby, PJ (2015). "Drug discovery approaches to irritable bowel syndrome". Expert Opinion on Drug Discovery. 10 (8): 809–24. doi:10.1517/17460441.2015.1049528. PMID   26193876. S2CID   207494271.
  6. ↑ "Director profile: Mark Currie, Ph.D." MUSC Foundation for Research Development. Archived from the original on 16 April 2018. Retrieved 15 April 2018.
  7. ↑ "Microbia Announces Name Change to Ironwood Pharmaceuticals".
  8. ↑ "Ironwood's I.P.O. Disappoints". New York Times DealBook. February 4, 2010.
  9. ↑ McBride, Ryan (22 September 2010). "Ironwood Pharmaceuticals Sells Struggling Microbia Subsidiary to Royal DSM". Xconomy.
  10. ↑ "Linaclotide - Ironwood Pharmaceuticals". AdisInsight. Retrieved 15 April 2018.
  11. ↑ "US label for linaclotide" (PDF). FDA. January 2017. Retrieved 15 April 2018. For label updates see FDA index page for NDA 202811
  12. ↑ "UK label: Linaclotide Summary of Product Characteristics". Electronic Medicines Compendium. September 2017. Retrieved 15 April 2018.
  13. ↑ Nocera, Joe (9 January 2018). "How Allergan Continues to Make Drug Prices Insane". Bloomberg News.
  14. ↑ Jones, Stacy; Burdette, kacy; Wieczner, Jen (July 30, 2015). "From Actavis to Allergan: One pharma company's wild dealmaking journey". Fortune.
  15. ↑ "8-K" (PDF). Ironwood. 31 January 2017. Archived from the original (PDF) on 15 April 2018. Retrieved 15 April 2018.
  16. ↑ "Recanaclotide - Ironwood Pharmaceuticals". AdisInsight. Retrieved 15 April 2018.
  17. ↑ "BNC 210". AdisInsight. Retrieved 15 April 2018.
  18. ↑ Tirrell, Meg (2018-04-09). "Biotech activist Alex Denner's next target: Ironwood Pharma". CNBC. Retrieved 2018-05-03.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.